Results with TRUQAP
in combination with abiraterone + prednisone

TRUQAP in combination* helped people get more time without their cancer growing or spreading vs abiraterone + prednisone

TRUQAP in combination* delivered a median of 33.2 months without cancer growing or spreading vs 25.7 months with abiraterone + prednisone—a difference of 7.5 months. Results may vary.

TRUQAP in combination* (n=507)

Placebo + abiraterone (n=505)

median
rPFS

33.2 months

median
rPFS

25.7 months

TRUQAP in combination*
slowed
the growth
and spread of the
cancer for
~8 months longer
than
abiraterone.

rPFS is a measure of how long a treatment keeps cancer from growing or spreading. Median rPFS is the time point at which half the patients have experienced disease progression. Median is the middle number in a group of numbers listed from lowest to highest.

*Combination therapy: TRUQAP + abiraterone + prednisone.

Abiraterone was taken with prednisone.

How TRUQAP was studied

TRUQAP was studied in a global clinical trial that included 1,012 people with metastatic* prostate cancer and PTEN deficiency.

The study group included:

Clinical Trial Participant Breakdown Of 1,012 People Clinical Trial Participant Breakdown Of 1,012 People

Two of the study's main goals were:

Number 1 IconNumber 1 IconSee how well the combination therapy
could
keep cancer from growing or spreading vs abiraterone + prednisone

Number 2 IconNumber 2 IconDetermine the safety of TRUQAP in combination

icon icon

Talk to your doctor about getting tested for PTEN deficiency.

*Metastatic=cancer that has spread to other parts of the body.

All patients were also taking ADT.

Combination therapy: TRUQAP + abiraterone + prednisone.

ADT=androgen deprivation therapy;
IHC=immunohistochemistry; PTEN=phosphatase and tensin homolog;
rPFS=radiographic progression-free survival.

back to top button